MX2014016114A - Metodo a base de euglobulina para determinar la actividad biologica de defibrotido. - Google Patents
Metodo a base de euglobulina para determinar la actividad biologica de defibrotido.Info
- Publication number
- MX2014016114A MX2014016114A MX2014016114A MX2014016114A MX2014016114A MX 2014016114 A MX2014016114 A MX 2014016114A MX 2014016114 A MX2014016114 A MX 2014016114A MX 2014016114 A MX2014016114 A MX 2014016114A MX 2014016114 A MX2014016114 A MX 2014016114A
- Authority
- MX
- Mexico
- Prior art keywords
- defibrotide
- biological activity
- determining
- euglobulin
- based method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/968—Plasmin, i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe un método para determinar la actividad biológica del defibrótido, el cual comprende las etapas: a) poner en contacto el defibrótido, la euglobulina de mamífero y un sustrato específico con la plasmina que, por la reacción con la plasmina, proporcionen un producto medible; y b) medir la cantidad de producto formada en tiempos sucesivos, a modo de determinar la actividad biológica del defibrótido. Las formulaciones líquidas de defibrótido también se describen, preferiblemente las soluciones acuosas, que tienen una actividad biológica definida y, particularmente, que tienen una actividad de 25 a 35 IU/mg de defibrótido, preferiblemente de 27.5 a 32.5 IU/mg y, preferiblemente, de 28 a 32 IU/mg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2012/000193 WO2013190582A1 (en) | 2012-06-22 | 2012-06-22 | Euglobulin-based method for determining the biological activity of defibrotide |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014016114A true MX2014016114A (es) | 2015-09-23 |
MX352085B MX352085B (es) | 2017-11-08 |
Family
ID=46829846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014016114A MX352085B (es) | 2012-06-22 | 2012-06-22 | Método a base de euglobulina para determinar la actividad biológica de defibrótido. |
Country Status (17)
Country | Link |
---|---|
US (6) | US9902952B2 (es) |
EP (1) | EP2864496B2 (es) |
JP (1) | JP6198821B2 (es) |
KR (4) | KR102038357B1 (es) |
CN (2) | CN104619857A (es) |
AU (1) | AU2012383169B2 (es) |
BR (1) | BR112014031934B1 (es) |
CA (1) | CA2874960C (es) |
DK (1) | DK2864496T4 (es) |
ES (1) | ES2660969T5 (es) |
HK (1) | HK1208503A1 (es) |
IL (1) | IL236132B (es) |
IN (1) | IN2014DN10584A (es) |
MX (1) | MX352085B (es) |
RU (1) | RU2627177C2 (es) |
SG (1) | SG11201408481UA (es) |
WO (1) | WO2013190582A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107007617A (zh) | 2010-11-12 | 2017-08-04 | 真蒂奥姆责任有限公司 | 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd) |
US9902952B2 (en) | 2012-06-22 | 2018-02-27 | Gentrum S.R.L. | Euglobulin-based method for determining the biological activity of defibrotide |
EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
EP3574514A4 (en) * | 2017-01-25 | 2020-11-18 | Kemet Electronics Corporation | SELF-SHOCKING MLCC NETWORK |
MX2020001337A (es) | 2017-08-03 | 2020-09-09 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones que comprenden un acido nucleico en una alta concentracion. |
BR112020020865A2 (pt) | 2018-04-12 | 2021-01-19 | Jazz Pharmaceuticals, Inc. | Defibrotida para prevenção e tratamento da síndrome de liberação de citocinas e neurotoxicidade associadas à imunodepleção |
WO2020118165A1 (en) | 2018-12-07 | 2020-06-11 | Jazz Pharmaceuticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
WO2021174039A1 (en) | 2020-02-28 | 2021-09-02 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899481A (en) | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
DE2154279A1 (de) | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
IT1043823B (it) | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
DE2812943C3 (de) | 1978-03-23 | 1981-05-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma |
US4853221A (en) | 1980-11-13 | 1989-08-01 | Warner-Lambert Company | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer |
IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
IT1206341B (it) | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
US4694134A (en) | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
US5223609A (en) | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
US5231006A (en) | 1986-10-16 | 1993-07-27 | Behringwerke Aktiengesellschaft | Method for the determination of plasminogen |
US4753221A (en) | 1986-10-22 | 1988-06-28 | Intravascular Surgical Instruments, Inc. | Blood pumping catheter and method of use |
JP2907447B2 (ja) | 1988-08-24 | 1999-06-21 | 中外製薬株式会社 | 抗血栓剤 |
IT1231509B (it) | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
JPH0539280A (ja) * | 1990-07-20 | 1993-02-19 | Takeda Chem Ind Ltd | サツカロアスコルビン酸誘導体および血栓症予防治療剤 |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
US5977083A (en) | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
US5624912A (en) | 1991-08-21 | 1997-04-29 | Burcoglu; Arsinur | Method of treating HIV infection and related secondary infections with defibrotide |
US6699985B2 (en) | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
IT1252174B (it) | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
JPH08127539A (ja) | 1994-10-31 | 1996-05-21 | Ajinomoto Co Inc | ヒトil−11を含有する末梢血幹細胞増加剤 |
WO1996016987A1 (fr) | 1994-11-30 | 1996-06-06 | Chugai Seiyaku Kabushiki Kaisha | Facteur thrombocytotique |
WO1998001151A1 (fr) | 1996-07-10 | 1998-01-15 | Meiji Milk Products Co., Ltd. | Nouvelle utilisation de la famille mk comme facteur hematopoietique |
WO1998048843A1 (en) | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
JP2002512508A (ja) | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Dnaメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
US6177545B1 (en) | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
DE19740384A1 (de) | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
GB9719161D0 (en) * | 1997-09-09 | 1997-11-12 | Glaxo Group Ltd | New therapeutic method |
US6573372B2 (en) | 1999-01-07 | 2003-06-03 | Heska Corporation | Feline immunoglobulin E molecules and compositions there of |
EP1206234A4 (en) | 1999-06-03 | 2005-06-01 | Jessie L S Au | METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH |
DE69928778T2 (de) | 1999-06-08 | 2006-07-06 | Gentium S.P.A., Villa Guardia | Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln |
EP1147777A1 (en) | 2000-04-18 | 2001-10-24 | Crinos Industria Farmacobiologica S.p.A. | Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors |
US8771663B2 (en) | 2000-04-18 | 2014-07-08 | Gentium Spa | Formulation having mobilising activity |
WO2002057414A2 (en) | 2000-10-20 | 2002-07-25 | Expression Diagnostics, Inc. | Leukocyte expression profiling |
CA2430341A1 (en) | 2000-11-28 | 2002-06-06 | The University Of Chicago | Genetically engineered herpes virus for the treatment of cardiovascular disease |
RU2003123101A (ru) | 2000-12-29 | 2005-03-10 | Сейвиент Фармасьютикэлс, Инк. (Us) | Изолированные молекулы, включающие эпитопы, содержащие сульфатированные остатки, антитела для эпитопов и их использование |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US6770753B2 (en) | 2001-07-05 | 2004-08-03 | The Trustees Of Columbia University In The City Of New York | Phosphorothioate antisense heparanase oligonucleotides |
AU2002353783A1 (en) | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
EP1325962A1 (en) | 2001-12-17 | 2003-07-09 | Gentium S.p.A. | A method for determining the biological activity of defibrotide |
CN1304011C (zh) | 2002-05-31 | 2007-03-14 | 雷根斯堡大学医学院 | 保护性寡聚脱氧核糖核苷酸的制药用途 |
US20050215498A1 (en) | 2002-05-31 | 2005-09-29 | Guenther Eissner | Method for the protection of endothelial and epithclial cells during chemotherapy |
JP2005536199A (ja) | 2002-07-01 | 2005-12-02 | サビエント ファーマシューティカルズ,インコーポレイティド | 抗体及びそれらの使用 |
CN100345593C (zh) | 2002-08-06 | 2007-10-31 | 东丽株式会社 | 用于制备肾脏疾病的治疗或预防药物中的用途 |
US20050196382A1 (en) | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
DE10244453A1 (de) | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
WO2005089503A2 (en) | 2004-03-19 | 2005-09-29 | Progenics Pharmaceuticals, Inc. | Cd4-igg2 formulations |
EP1802766A4 (en) * | 2004-09-22 | 2008-05-21 | Univ Colorado | METHODS OF GLOBALLY TESTING COAGULATION AND FIBRINOLYSIS |
US7723127B2 (en) | 2005-03-03 | 2010-05-25 | Novx Systems Inc. | Immunoassay with extended dynamic range |
JP2008531647A (ja) | 2005-03-03 | 2008-08-14 | ゲンチウム エスピーエー | 抗腫瘍作用を有する製剤 |
WO2006119619A1 (en) | 2005-05-06 | 2006-11-16 | Replicor Inc. | Oligonucleotides inhibiting cell proliferation |
EP1872787A1 (en) | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
EP1982722A1 (en) | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
FR2917172B1 (fr) * | 2007-06-07 | 2014-01-03 | Inst Nat Sante Rech Med | Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation |
EP2183598A1 (en) | 2007-07-13 | 2010-05-12 | Elan Pharmaceuticals Inc. | Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase |
EP2103689A1 (en) | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
WO2009126310A2 (en) | 2008-04-10 | 2009-10-15 | Massachusetts Institute Of Technology | Methods for identification and use of agents targeting cancer stem cells |
AU2010241567B2 (en) * | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
WO2011057143A1 (en) * | 2009-11-06 | 2011-05-12 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for simultaneous assay of thrombin and plasmin generation |
CN107007617A (zh) | 2010-11-12 | 2017-08-04 | 真蒂奥姆责任有限公司 | 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd) |
US9902952B2 (en) | 2012-06-22 | 2018-02-27 | Gentrum S.R.L. | Euglobulin-based method for determining the biological activity of defibrotide |
EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
MX2020001337A (es) | 2017-08-03 | 2020-09-09 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones que comprenden un acido nucleico en una alta concentracion. |
-
2012
- 2012-06-22 US US14/408,272 patent/US9902952B2/en active Active
- 2012-06-22 CA CA2874960A patent/CA2874960C/en active Active
- 2012-06-22 EP EP12756826.9A patent/EP2864496B2/en active Active
- 2012-06-22 JP JP2015517926A patent/JP6198821B2/ja active Active
- 2012-06-22 ES ES12756826T patent/ES2660969T5/es active Active
- 2012-06-22 CN CN201280074120.5A patent/CN104619857A/zh active Pending
- 2012-06-22 KR KR1020197003854A patent/KR102038357B1/ko active IP Right Grant
- 2012-06-22 KR KR20157001763A patent/KR20150044877A/ko active Search and Examination
- 2012-06-22 KR KR1020187024264A patent/KR101948243B1/ko active IP Right Grant
- 2012-06-22 BR BR112014031934-0A patent/BR112014031934B1/pt active IP Right Grant
- 2012-06-22 CN CN201910228570.9A patent/CN110079580B/zh active Active
- 2012-06-22 RU RU2014149089A patent/RU2627177C2/ru active
- 2012-06-22 IN IN10584DEN2014 patent/IN2014DN10584A/en unknown
- 2012-06-22 DK DK12756826.9T patent/DK2864496T4/da active
- 2012-06-22 KR KR1020197028118A patent/KR20190112197A/ko not_active Application Discontinuation
- 2012-06-22 MX MX2014016114A patent/MX352085B/es active IP Right Grant
- 2012-06-22 SG SG11201408481UA patent/SG11201408481UA/en unknown
- 2012-06-22 AU AU2012383169A patent/AU2012383169B2/en active Active
- 2012-06-22 WO PCT/IT2012/000193 patent/WO2013190582A1/en active Application Filing
-
2014
- 2014-12-08 IL IL236132A patent/IL236132B/en active IP Right Grant
-
2015
- 2015-09-17 HK HK15109110.9A patent/HK1208503A1/xx active IP Right Maintenance
-
2017
- 2017-12-18 US US15/844,801 patent/US20180334672A1/en not_active Abandoned
-
2020
- 2020-03-12 US US16/816,741 patent/US11085043B2/en active Active
-
2021
- 2021-08-06 US US17/396,028 patent/US11746348B2/en active Active
- 2021-08-27 US US17/459,169 patent/US11236328B2/en active Active
-
2023
- 2023-07-12 US US18/351,241 patent/US20230357762A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2874960C (en) | Euglobulin-based method for determining the biological activity of defibrotide | |
EP3955004A3 (en) | Use of fatty acids in methods for detecting cancer | |
MX348612B (es) | Microorganismos y metodos para producir 2,4 - pentadienoato, butadieno, propileno, 1,3 - butanodiol y alcoholes relacionados. | |
WO2012078806A3 (en) | Non-gaming on-line achievement awards | |
NZ617003A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
EP2521587A4 (en) | RELEASE SYSTEM | |
MY158663A (en) | Fermentation broth formulations | |
WO2010101628A3 (en) | Methods and products for in vivo enzyme profiling | |
IN2014MN00848A (es) | ||
WO2014060785A3 (en) | DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR | |
WO2011104517A3 (en) | Capacitance detection in electrochemical assay | |
MY171760A (en) | Microorganisms and methods for the production of caprolactone | |
MX349801B (es) | Sustratos de enzimas de ácido nucleico. | |
WO2013170963A3 (en) | Enzymatic synthesis of l-nucleic acids | |
MX365302B (es) | Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno. | |
WO2012177983A3 (en) | Microorganisms for producing ethylene glycol and methods related thereto | |
MX344896B (es) | Método de operación de la fermentación de un substrato gaseoso que contiene monóxido de carbono. | |
BR112015032515A2 (pt) | método para a produção de um açúcar líquido, açúcar líquido, açúcar sólido, açúcar líquido ou açúcar sólido derivado e método para a produção de uma substância química | |
WO2008114544A1 (ja) | 細胞周期可視化プローブ | |
BR112015010407A2 (pt) | Métodos para obter óleo a partir de milho | |
GB2542576A (en) | Method and kit of detecting the absence of micro-oranisms | |
WO2013029631A3 (en) | Enzyme detection by microfluidics | |
GB201320456D0 (en) | Oxidation/reduction measurement | |
AR093819A1 (es) | Metodo a base de euglobulina para determinar la actividad biologica de defibrotida | |
ITMI20121259A1 (it) | Utilizzo di un substrato in un procedimento per misurare l'attivita' di enzimi proteolitici disponibili. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: PHILIPS LIGHTING HOLDING B.V. |
|
FG | Grant or registration |